Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Shionogi & Co. Ltd.
Industry Sector: HealthTechnology
CEO: Isao Teshirogi, PhD
Number Of Employees: 4,959
Enterprise Value: $12,685,594,172
PE Ratio: 11.45
Exchange/Ticker 1: Tokyo:4507
Exchange/Ticker 2: N/A
Latest Market Cap: $13,100,263,141
BioCentury | Jun 11, 2024
Product Development
Clinical Report: Shionogi mulls next steps after underwhelming obesity readout
Plus: Bluejay, Vir give HDV updates; Skye’s miss in glaucoma; and more
BioCentury | May 14, 2024
Product Development
Clinical Report: MacroGenics faces ADC safety concerns
Plus data from CytomX, Merck, Regeneron and more
BioCentury | May 14, 2024
Politics, Policy & Law
Biosecure revised, and venture rounds, deals of note: a BioCentury podcast
What’s new in legislation seeking to rein in influence of China’s CDMOs
BioCentury | May 14, 2024
Deals
Deals Report: Sanofi-Novavax to co-commercialize Nuvaxovid, develop combination vaccines
Plus: Maze finds Pompe disease program partner in Shionogi, and updates from Takeda-AC Immune, Sanofi-Fulcrum and more
BioCentury | Feb 28, 2024
Product Development
Clinical report: Early efficacy signals triple Janux’s value; Tarsus reveals tick-killing data
Plus: readouts from Sanofi in hives, GSK in gonorrhea; Shionogi’s digital therapeutic and InDex’s next steps
BioCentury | Feb 7, 2024
Management Tracks
Verily names Myoung Cha as chief product officer
Plus: New CFO for Innovent and updates from Takeda, Shionogi, Lexeo, Stuart, Arcellx and more
BioCentury | Dec 22, 2023
Discovery & Translation
Move over oncology — I&I will write the next big stories in innovation
Biotech execs, investors eye immunology and inflammation, plus neurology as innovation drivers, but precision medicine still to prove itself: a BioCentury survey
BioCentury | Nov 9, 2023
Emerging Company Profile
OrsoBio: bringing obesity mechanisms to bear
Samsara-incubated company garners $60M series A to advance multi-target pipeline assembled via in-licensing
BioCentury | Oct 27, 2023
Data Byte
Quarterly earnings on deck next week
At least 10 biopharmas are slated to report financial results next week
BioCentury | Sep 14, 2023
Regulation
Sept. 13 Quick Takes: Madrigal gets March PDUFA date for NASH therapy
Plus: Rocket parlays gene therapy update into $175M raise and updates from DalCor, Mironid, Crinetics, Shionogi, Hasten, Dewpoint and Orchid
Items per page:
1 - 10 of 844